Metabolic reprogramming of three major nutrients in platinum-resistant ovarian cancer

被引：1
|
作者：
Yan, Jinbowen [1 ]
Xu, Fangzhi [2 ]
Zhou, Dan [1 ]
Zhang, Shuo [1 ]
Zhang, Bo [1 ]
Meng, Qingwei [1 ]
Lv, Qiubo [1 ]
机构：
[1] Chinese Acad Med Sci, Beijing Hosp, Inst Geriatr Med, Dept Obstet & Gynecol,Natl Ctr Gerontol, Beijing, Peoples R China
[2] Chinese Acad Med Sci, Inst Geriatr Med, Key Lab Geriatr, Beijing Hosp,Natl Ctr Gerontol,Natl Hlth Commiss,B, Beijing, Peoples R China
来源：
FRONTIERS IN ONCOLOGY | 2023年 / 13卷
关键词：
ovarian cancer; platinum resistance; metabolic reprogramming; glucose metabolism; lipid metabolism; amino acid metabolism; MOLECULAR-MECHANISMS; EXPRESSION; CELLS; ACID; CHEMORESISTANCE; CISPLATIN; PROLIFERATION; METASTASIS; HALLMARKS; CARCINOMA;
D O I：
10.3389/fonc.2023.1231460
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Metabolic reprogramming is a phenomenon in which cancer cells alter their metabolic pathways to support their uncontrolled growth and survival. Platinum-based chemotherapy resistance is associated with changes in glucose metabolism, amino acid metabolism, fatty acid metabolism, and tricarboxylic acid cycle. These changes lead to the creation of metabolic intermediates that can provide precursors for the biosynthesis of cellular components and help maintain cellular energy homeostasis. This article reviews the research progress of the metabolic reprogramming mechanism of platinumbased chemotherapy resistance caused by three major nutrients in ovarian cancer.
引用
收藏
页数：8
相关论文
共 50 条
  • [1] Treosulfan in platinum-resistant ovarian cancer
    Olesen, Katrine Dam
    Larsen, Anja Tolstrup Raedkjaer
    Jensen, Lars Henrik
    Steffensen, Karina Dahl
    Sondergaard, Stine Rauff
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 (07) : 1045 - 1051
  • [2] Immunotherapy for platinum-resistant ovarian cancer
    Bogani, Giorgio
    Lopez, Salvatore
    Mantiero, Mara
    Ducceschi, Monika
    Bosio, Sara
    Ruisi, Simona
    Sarpietro, Giuseppe
    Guerrisi, Rocco
    Brusadelli, Claudia
    Dell'Acqua, Andrea
    Di Donato, Violante
    Raspagliesi, Francesco
    GYNECOLOGIC ONCOLOGY, 2020, 158 (02) : 484 - 488
  • [3] Serine auxotrophy: A novel metabolic vulnerability of platinum-resistant ovarian cancer?
    Tom Van Nyen
    Duarte, Joao A. G.
    Rossi, Matteo
    Planque, Melanie
    Zaal, Esther
    Talebi, Ali
    Moens, Stijn
    Eelen, Guy
    Horlings, Hugo
    Swinnen, Johan
    Berkers, Celia
    Carmeliet, Peter
    Agami, Reuven
    Fendt, Sarah-Maria
    Lambrechts, Diether
    Annibali, Daniela
    Amant, Frederic
    CLINICAL CANCER RESEARCH, 2020, 26 (13) : 76 - 77
  • [4] Gemcitabine and anthracyclines in platinum-resistant ovarian cancer
    Galligioni, E.
    Arcuri, C.
    Sorio, R.
    Griso, C.
    ANNALS OF ONCOLOGY, 2006, 17 : V195 - V198
  • [5] Mirvetuximab Soravtansine for platinum-resistant Ovarian Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2023, 83 (08) : 882 - 882
  • [6] ECONOMIC BURDEN IN PLATINUM-RESISTANT OVARIAN CANCER
    Indukuri, Nikhila
    Musat, Mihaela
    Chavez, Gordon
    Proescholdt, Christina
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A142 - A142
  • [7] A source of hope for platinum-resistant ovarian cancer?
    Blagden, Sarah P.
    Nicum, Shibani
    LANCET, 2021, 397 (10271): : 254 - 256
  • [8] Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
    Gonzalez-Ochoa, Eduardo
    Veneziani, Ana C.
    Oza, Amit M.
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2023, 17
  • [9] Topotecan in platinum-resistant epithelial ovarian cancer
    Karabulut, B
    Sezgin, C
    Terek, MC
    Uslu, R
    Sanli, UA
    Akman, L
    Ozsaran, A
    Dikmen, Y
    Goker, E
    CHEMOTHERAPY, 2005, 51 (06) : 347 - 351
  • [10] ATR Inhibitors in Platinum-Resistant Ovarian Cancer
    Li, Siyu
    Wang, Tao
    Fei, Xichang
    Zhang, Mingjun
    CANCERS, 2022, 14 (23)
12345